RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

Written by Petra Hegmann on 4th October 2021. Posted in Client News.

• Previous
• Next